Please login to the form below

Not currently logged in
Email:
Password:

metastatic colorectal cancer

This page shows the latest metastatic colorectal cancer news and features for those working in and with pharma, biotech and healthcare.

Pfizer adds Array to cancer arsenal with $11bn acquisition

Pfizer adds Array to cancer arsenal with $11bn acquisition

However its greatest potential is in colorectal cancer.  A triplet combination of Braftovi and Mektovi plus cetuximab in the Phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer (mCRC) showed ... Analysts at Evaluate Pharma forecast Braftovi

Latest news

More from news
Approximately 2 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.

  • Pharma deals during February 2014 Pharma deals during February 2014

    awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... colorectal cancer and gastrointestinal stromal

  • Pharma deals during September 2012 Pharma deals during September 2012

    advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).

  • Evidence-based patient pathways for mCRC Evidence-based patient pathways for mCRC

    Timescale:January – May 2011. People in the UK are dying prematurely from metastatic colorectal cancer (mCRC) in what appears to be a “postcode lottery” for accessing treatment and specialist support. ... People in the UK are dying prematurely from

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

  • Boston Biomedical appoints commercial head Boston Biomedical appoints commercial head

    Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic ... colorectal cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...

Infographics